文献速递生殖医学

医学辅助生殖中的激素药物:患者评估的系统综述

Hormonal medication in medically assisted reproduction: a systematic review of assessments from patients.
PubMed 文献 · Reprod Biomed Online · 2019-01-19

本系统综述检索 Medline、CINAHL 和 PsycINFO,纳入 35 项研究,评估女性生育患者对七类激素药物特征的书面评价。所纳入研究未采用有效可靠工具,且对全球常用药物均未提供全部七类特征的患者评估;卵母细胞触发药物无证据,垂体静息诱导药物证据 scarce。综述呼吁开展采用有效可靠工具询问患者的随机对照试验。

要点

  • 所纳入 35 项研究均未使用有效可靠工具评估患者对激素药物的看法。
  • 卵母细胞触发药物无患者评估证据,垂体静息诱导药物证据 scarce。
  • 卵巢刺激和黄体支持药物有一般副作用(多为头痛)和局部副作用(多为疼痛)等证据。

核心结论

  • 本综述呼吁开展采用有效可靠工具询问患者的随机对照试验。
  • 同时,本综述汇总的最佳现有证据可整合入决策辅助工具,以促进个性化和知情的药物选择。

研究设计与样本

  • 系统综述,检索 Medline、CINAHL 和 PsycINFO 中女性生育患者对激素药物的书面评估。
  • 共纳入 35 项符合条件的研究,评估工具并区分常见(≥10%)与罕见的不良后果。

主要发现

  • 35 项符合条件的研究未依赖有效可靠工具,且对任何全球常用药物均未提供全部七类药物特征的患者评估。
  • 卵母细胞触发药物的证据缺失,垂体静息诱导药物的证据 scarce。
  • 卵巢刺激和黄体支持药物有一般副作用(多为头痛)、局部副作用(多为疼痛)、「家庭生活干扰」和「心理幸福感影响」的证据。
  • 仅卵巢刺激药物有「易用性」和「所需教育」的证据。
  • 「工作生活干扰」和「依从性担忧」的证据缺失。

临床怎么用

  • 本综述汇总的最佳现有证据可整合入决策辅助工具,以促进个性化和知情的药物选择。

局限性

  • 35 项符合条件的研究未依赖有效可靠工具。
  • 未对任何全球常用药物提供全部七类药物特征的患者评估。
  • 卵母细胞触发药物的证据缺失,垂体静息诱导药物的证据 scarce。
  • 「工作生活干扰」和「依从性担忧」的证据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several hormonal fertility medications have comparable effectiveness. A literature review was conducted into patients' assessments regarding seven medication characteristics including 'side effects' and 'ease of use'. Medline, CINAHL and PsycINFO were searched for female fertility patients' written assessments of a hormonal medication. The tools used were appraised and common (i.e. ≥10%) unpleasant consequences were distinguished from rare ones. The 35 eligible studies did not rely on valid and reliable tools and did not provide patient assessments regarding all seven medication characteristics for any of the globally used medications. Evidence on medications for oocyte triggering was absent and for induction of pituitary quiescence it was scarce. Regarding medications for ovarian stimulation and luteal support, evidence on general side effects (mostly headache), local side effects (mostly pain), 'interference with home life' and 'impact on psychological wellbeing' was found. Evidence on 'ease of use' and 'required education' was only identified for medication for ovarian stimulation. Evidence on 'interference with work life' and 'compliance worry' was absent. This review calls for randomized controlled trials questioning patients with valid and reliable tools. In the meantime, this review's summary of the best available evidence can be integrated in decision aids facilitating personalized and informed medication choices.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Lankreijer K, D'Hooghe TM, Apers S, et al. Hormonal medication in medically assisted reproduction: a systematic review of assessments from patients. Reprod Biomed Online. 2019. PMID: 30770286. doi:10.1016/j.rbmo.2018.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。